Nano Packaged Tamoxifen and Curcumin; Effective Formulation against Sensitive and Resistant MCF-7 Cells
| Author | Samira Hajigholami | en |
| Author | Ziba Veisi Malekshahi | en |
| Author | Narges Bodaghabadi | en |
| Author | Farhod Najafi | en |
| Author | Hadi Shirzad | en |
| Author | Majid Sadeghizadeh | en |
| Issued Date | 2018-01-31 | en |
| Abstract | Tamoxifen is routinely used for treatment of Estrogen-positive breast carcinoma. Approximately, 50% of patients with metastatic cancer will develop resistance to Tamoxifen. In this research, Tamoxifen was combined with the anti-cancer compound Curcumin. Diblocknanopolymer was used to package the new formulation of Curcumin and Tamoxifen. Anti-cancer efficacy of the obtained compound was evaluated in Tamoxifen-sensitive (TS). MCF-7, Tamoxifen-resistant (TR) MCF-7 cancer cells and Fibroblast cells. MTT assay was used to evaluate anti-proliferation and toxicity. Flow cytometry and Annexin-V-FLUOS were used to assay anti-proliferation and induction of apoptosis respectively. Our results indicate that the obtained nano-compound is less toxic to normal cells compared to Tamoxifen alone, and has higher anti-proliferation and pro-apoptotic activity on TS-MCF-7 and TR-MCF-7. The nanopolymer reduces the Tamoxifen toxicity in normal cells and counters the developed resistance to the drug in cancer cells. | en |
| DOI | https://doi.org/10.22037/ijpr.2018.1965 | en |
| Keyword | Breast Cancer | en |
| Keyword | Curcumin | en |
| Keyword | Tamoxifen | en |
| Keyword | Polymer Nano-carrier | en |
| Publisher | Brieflands | en |
| Title | Nano Packaged Tamoxifen and Curcumin; Effective Formulation against Sensitive and Resistant MCF-7 Cells | en |
| Type | Original Article | en |